What is Protagonist Therapeutics's D&A?

Protagonist Therapeutics (PTGX) reported D&A of $407K in Q1 2026.

How has Protagonist Therapeutics's D&A changed year-over-year?

Protagonist Therapeutics's D&A increased by 70.3% year-over-year, from $239K to $407K.

What is the long-term trend for Protagonist Therapeutics's D&A?

Over 4 years (2021 to 2025), Protagonist Therapeutics's D&A has grown at a 12.0% compound annual growth rate (CAGR), from $813K to $1.28M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Protagonist Therapeutics PTGX D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

Eli LillyLLY

$509M+9.9%

AmgenAMGN

$1.12B-19.5%

IncyteINCY

$23.8M+6.4%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

Apogee Therapeutics, Inc.APGE

——

Other financials

Income statement

See full

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

See full

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

See full

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

See full

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

See full

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

See full

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Protagonist Therapeutics's D&A?: Protagonist Therapeutics (PTGX) reported D&A of $407K in Q1 2026.
How has Protagonist Therapeutics's D&A changed year-over-year?: Protagonist Therapeutics's D&A increased by 70.3% year-over-year, from $239K to $407K.
What is the long-term trend for Protagonist Therapeutics's D&A?: Over 4 years (2021 to 2025), Protagonist Therapeutics's D&A has grown at a 12.0% compound annual growth rate (CAGR), from $813K to $1.28M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.